Short Bowel Syndrome and Kidney Transplantation: Challenges, Outcomes, and the Use of Teduglutide
Table 1
Demographics, survival, and graft function in kidney transplant recipients with short bowel syndrome (including the current report).
Number of transplants
20
Age (years)–median (range)
53 (18-74)
Male sex–no. (%)
13 (65)
Cause of SBS–no. (%)
Crohn’s
15 (75)
Obstruction
2 (10)
Other
3 (15)
Cause of ESKD–no. (%)
Oxalate nephropathy
8 (40)
Nephrolithiasis
4 (20)
Glomerulosclerosis
3 (15)
Other
5 (25)
Follow-up (years)–median (range)
2.05 (0.04-7)
Functioning graft–no. (%)
18 (90)
Death–no. (%)
1 (5)
eGFR (ml/min) at last follow-up–median (range)
37.5 (14-122)
Immunosuppression–no. (%)
MMF, CNI, and steroids
10 (50)
Azathioprine
3 (15)
Sirolimus
2 (10)
Unknown
4 (20)
Steroid free
1 (5)
Complications–no. (%)
None
5 (25)
Rejection
3 (15)
Acute allograft dysfunction
12 (60)
Oxalate deposition
5 (25)
Infections
3 (15)
Abbreviations: CNI: calcineurin inhibitors: eGFR: estimated glomerular filtration rate; ESKD: end-stage kidney disease; MMF: mycophenolate mofetil; SBS: short bowel syndrome. Of note, the cumulative number of complications exceeds the number of transplant cases as some patients developed more than one complication.
